New Phase 3 trials registered, week of November 9, 2026: 2 industry trials
Industry sponsors registered 2 Phase 3 trials on ClinicalTrials.gov so far in the week of November 9 to 15, 2026. They plan to enroll 729 participants in all; the largest, CSPC Megalith Biopharmaceutical Co.,Ltd.'s SYS6010 trial, plans to enroll 585.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 15, 2026.
The trials
- CSPC Megalith Biopharmaceutical registers Phase III trial of enlonstobart with SYS6010. Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Condition: Esophageal Squamous Cell Carcinoma. Interventions: SYS6010, SG001. Phase: Phase 3. Planned enrollment: 585. Planned primary completion: December 2029. First posted November 9, 2026. Record: NCT07924111.
- Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia. Sponsor: Ascendis Pharma A/S. Condition: Achondroplasia. Intervention: Dual therapy with navepegritide and lonapegsomatropin. Phase: Phase 3. Planned enrollment: 144. Planned primary completion: September 2028. First posted November 9, 2026. Record: NCT07924059 (cAtCH).
By the numbers
- Trials: 2, from 2 lead sponsors.
- Planned enrollment: 729 in all across 2 trials; median 365 per trial.
- Largest: CSPC Megalith Biopharmaceutical Co.,Ltd.'s SYS6010 trial, 585. Smallest: Ascendis Pharma A/S's cAtCH trial, 144.
- Phases as registered: 2 Phase 3.
- Planned primary completion: from September 2028 to December 2029.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.